Bladder Cancer

Papers
(The median citation count of Bladder Cancer is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Single-cell RNA sequencing and spatial transcriptome analysis in bladder cancer: Current status and future perspectives16
Association of CCL2/CCR2 gene polymorphisms and bladder cancer risk in a hispanic-rich US population15
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer13
Predicting Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer: Systematic Review on the Performance of Risk Stratification Models12
Metastasis-directed radiotherapy for oligometastatic urothelial carcinoma of the bladder and upper tract10
Patterns of care and associated social determinants of health in the definitive treatment of localized muscle-invasive bladder cancer patients10
Comparison of Robotic vs Open Cystectomy: A Systematic Review9
No Association Between BCG Instillations and COVID-19 Incidence in a Dutch Non-Muscle Invasive Bladder Cancer Cohort9
Intravesical instillation of chemotherapy before surgery for upper tract urothelial cancer7
Clinical Trials Corner Issue 9(2)7
Standard vs extended lymphadenectomy for muscle invasive bladder cancer7
Urologists and Advanced Practice Providers Evaluating Hematuria7
Evaluation of the Effects of Opium on the Expression of SOX2 and OCT4 in Wistar Rat Bladder6
Computational pathology in bladder cancer: A scoping review6
Clinical trials corner issue 12(1)6
Orthotopic bladder cancer preclinical models: Comprehensive review and technique optimization5
Clinical Trials Corner Issue 10(2)5
Expression of PD-1 and PD-L1 in BCG-treated NMIBC5
A New Standard of Care for Bladder Cancer5
Management of bladder cancer in kidney transplant recipients: A narrative review5
The role of blue light cystoscopy and additional operative evaluations during first surveillance after induction therapy for high-risk NMIBC4
Mechanism of Sex Differences in Bladder Cancer: Evident and Elusive Sex-biasing Factors4
Organoid models in bladder cancer: From bench to bedside?4
Analysis of sarcopenia indicators on survival prediction undergoing radical cystectomy4
Loss of Cxcr2 in Myeloid Cells Promotes Tumour Progression and T Cell Infiltration in Invasive Bladder Cancer4
Systemic induction therapy in patients with locally advanced or node-positive urothelial carcinoma: Evaluating treatment outcomes4
Non-Muscle Invasive Bladder Cancer: Many More Patients Die With It Than Of It4
Molecular Basis of Tumorigenesis of Bladder Cancer and Emerging Concepts in Developing Therapeutic Targets3
Y Chromosome Loss and Bladder Cancer3
Challenging Cases in Urothelial Cancer: Case 263
Immune Checkpoint Inhibitors in Metastatic Bladder and Other Solid Malignancies: How Long is Enough?3
Commentary on Novitas LCD3
Efficacy of Antibody Drug Conjugates Alone and in Combination with other Agents in Metastatic Urothelial Carcinoma: A Scoping Review2
Challenging Cases in Urothelial Cancer: Case 332
Platinum-based chemotherapy rechallenge or enfortumab vedotin after maintenance avelumab or pembrolizumab for locally advanced or metastatic urothelial carcinoma2
Circulating tumor DNA–guided adjuvant immunotherapy in muscle-invasive bladder cancer2
Open vs Robotic Surgery2
SH3BP5-AS1/IGF2BP2/VDAC2 Axis Promotes the Apoptosis and Ferroptosis of Bladder Cancer Cells2
Challenging Cases in Urothelial Cancer: Case 272
Adjuvant Chemotherapy Plus Radiotherapy versus Chemotherapy Alone for Locally Advanced Bladder Cancer after Radical Cystectomy2
Editorial Concerning “The Association Between Diabetes Medication Use and Tumour Characteristics at Diagnosis in Patients with Urothelial Carcinoma: A Retrospective Registry-Based Study”2
Urothelial carcinoma and the potential clinical application of urinary extracellular vesicles: Current Status and prospects2
Electromotive Drug Administration Chemotherapy with Mitomycin C Versus Bacillus Calmette-Guerin for the Treatment of Non-Muscle Invasive Bladder Cancer2
Does Blue Light Cystoscopy Reduce Recurrences of Non-Muscle Invasive Bladder Cancer?2
Patterns of Smoking Cessation Strategies and Perception of E-cigarette Harm Among Bladder Cancer Survivors2
Novel Delivery Mechanisms for Existing Systemic Agents and Emerging Therapies in Bladder Cancer2
Switch Maintenance Therapy for Metastatic Urothelial Carcinoma2
MHC I Expression Predicts Response to Checkpoint Inhibitors in Metastatic Urothelial Carcinoma but Lacks Prognostic Value in Localized Disease1
Interdisciplinary Swiss consensus recommendations for follow-up after radical cystectomy and trimodal treatment for muscle-invasive bladder cancer1
Factors Influencing Patient Decision-Making in the Treatment of Muscle-Invasive Bladder Cancer1
Impact of Adjuvant Gemcitabine Containing Chemotherapy Following Radical Nephroureterectomy for Patients with Upper Tract Urothelial Carcinoma: Results from a Propensity-Score Matched Cohort Study1
Is There A Benefit of Restaging Transurethral Resection of Bladder Tumor Prior to Radical Cystectomy With or Without Neoadjuvant Chemotherapy?1
Neoadjuvant chemotherapy for high-risk upper tract urothelial cancer1
Multi-Center Assessment of Lymph-Node Density and Nodal-Stage to Predict Disease-Specific Survival in Patients with Bladder Cancer Treated by Radical Cystectomy1
Serum metabolomic analysis identified serum biomarkers predicting tumour recurrence after Bacillus Calmette–Guérin therapy in patients with non-muscle invasive bladder cancer1
Advancements in systemic therapy for muscle-invasive bladder cancer: A systematic review from the beginning to the latest updates1
NK Cell-Targeted Immunotherapies in Bladder Cancer: Beyond Checkpoint Inhibitors1
Impact of neighborhood deprivation on bladder cancer outcomes: A regional analysis1
The Evolution of Nadofaragene Firadenovec: A Review and the Path Forward1
Challenging Cases in Urothelial Cancer: Case 30: Rare Complication of BCG1
Neoadjuvant Intravesical Chemotherapy for Non-muscle Invasive Bladder Cancer1
BCG therapy for bladder cancer: Exploring patient experiences and concerns through artificial intelligence-based social media analysis1
Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis1
Physical Activity and Health-related Quality of Life from Diagnosis to One Year After Radical Cystectomy in Patients with Bladder Cancer: A Longitudinal Cohort Study1
Urethral Melanoma – Clinical, Pathological and Molecular Characteristics1
When a ‘routine’ TURBT is not routine: Lessons from SEER-medicare1
Higher resilience in radical cystectomy patients is associated with improved health related quality of life post-operatively1
Clinical Trials Corner Issue 9(4)1
What is a Bladder Cancer Molecular Subtype?1
A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating Non-Muscle Invasive Bladder Cancer: HIVEC-E1
An Association Study of Germline Variants in Bladder Cancer-Related Genes with the Prognosis of Non-Muscle Invasive Bladder Cancer1
Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile1
BCG in Immunocompromised Patients: Is it effective? Is it safe?1
Longitudinal Analysis of Bladder Cancer-Specific Mortality Trends in the United States1
0.075171947479248